Like prostate cancer, bladder cancer patients may benefit from anti-androgen therapy

September 24, 2012

Bladder cancer patients whose tumors express high levels of the protein CD24 have worse prognoses than patients with lower CD24. A University of Colorado Cancer Center study published today in the Proceedings of the National Academy of Sciences shows that CD24 expression may depend on androgens – and that anti-androgen therapies like those currently used to treat prostate cancer may benefit bladder cancer patients.

"This is a major finding – development and spread to other organs depends significantly on CD24, which in turn depends on androgens like testosterone. By taking away these androgens, we may be able to greatly diminish the proliferative and metastatic power of bladder ," says the study's senior author, Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center.

Theodorescu and colleagues started with mouse models, showing that mice without the ability to make the protein CD24 had fewer primary bladder tumors and metastases ( spread to other organs) compared to mice with CD24 intact. This effect was most marked in male mice. The group moved to human tumor samples, showing that when patients were stratified according to the levels of CD24 expressed in their tumors, especially the male patients had poorer outcomes, including higher rates of relapse and shorter disease-free survival.

"To us, these sex-specific findings implied androgen involvement," Theodorescu says. Sure enough, when the group knocked down in human bladder cancer cell lines, they saw a corresponding drop in CD24 levels and also decreased cell proliferation. When they artificially added CD24, resumed regardless of androgen levels. In essence, androgen is effectively a hormonal switch that allowed the harmful effect of CD24 to flow.

Together, these finding imply not only a correlative but a causative effect of CD24 – that not only do high levels of CD24 mark more aggressive bladder tumors, but that CD24 in fact drives the aggressiveness of these tumors. While the protein CD24 is difficult to affect directly with current therapies, anti-androgen therapies that would diminish the tumor's ability to express CD24 are already in wide use for prostate cancer.

"We hope the results of these studies show the rationale for clinical studies of anti-androgen therapies with bladder cancer, especially in those tumors that happen to test markedly high in CD24 expression," Theodorescu says. "The next step is moving this promising therapy to clinical trials with human patients."

Explore further: Lack of oxygen in cancer cells leads to growth and metastasis

Related Stories

Lack of oxygen in cancer cells leads to growth and metastasis

September 13, 2012
(Medical Xpress)—It seems as if a tumor deprived of oxygen would shrink. However, numerous studies have shown that tumor hypoxia, in which portions of the tumor have significantly low oxygen concentrations, is in fact linked ...

Scientists identify overactive genes in aggressive breast cancers

June 1, 2011
Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that ...

Major study stops bladder cancer from metastasizing to lungs

March 12, 2012
The diagnosis of localized bladder cancer carries an 80 percent five-year survival rate, but once the cancer spreads, the survival rate at even three years is only 20 percent. A major study published today in the Journal ...

Protein RAL associated with aggressive characteristics in prostate, bladder and skin cancers

May 17, 2012
We have known for years that when the proteins RalA and RalB are present, cells in dishes copy toward aggressive forms of cancer. However, until this week, no study had explored the effects of RAL proteins in human cancers ...

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.